We offer integration of micronucleus assessments into repeat dose toxicity studies, the transgenic rodent mutation assay, or the combination acute micronucleus and comet assay. Our multi-endpoint assays are not only compound and cost efficient, but also help you support the 3Rs of nonclinical research.
The world’s demand for safe products is growing, and the demand for innovation in genetic toxicology and in vitro models is growing along with it. This is why we have expanded our genetic toxicology facilities by 30 percent, including new in vitro alternatives. Explore all of your genetic toxicology study options.
Over the past five years, we’ve invested more than $700 million in nonclinical development to enhance our capabilities for your programs. From expanded lab space in our U.S., European and Asia Pacific sites to state-of-the-art instrumentation and digitized workflows, we’ve innovated where it matters most to empower your healthcare mission.
